UCB SA (OTCMKTS:UCBJF) Short Interest Down 17.0% in October

UCB SA (OTCMKTS:UCBJF) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 403,500 shares, a drop of 17.0% from the October 15th total of 486,100 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is currently 4,035.0 days.

UCB Price Performance

OTCMKTS UCBJF opened at $194.76 on Friday. The firm’s fifty day moving average price is $181.53 and its 200 day moving average price is $157.20. UCB has a 12 month low of $69.70 and a 12 month high of $194.76. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.